迈蓝的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 7 条
2021
迈蓝就涉嫌限制Copaxone竞争起诉Teva
提起诉讼
Mylan Pharmaceuticals在联邦法院起诉Teva，指控其采取手段延迟多发性硬化症药物Copaxone面临的竞争。相关指控属于诉状中的主张，并非法院认定；报道时Teva尚未作出回应。
Mylan Pharmaceuticals 在联邦法院起诉 Teva，指控其采取手段延迟多发性硬化症药物 Copaxone 面临的竞争。报道未称这些指控已获法院认定，并指出 Teva 尚未回应。
来源摘录
With the suit just filed, Teva has not yet had time to file a response.
Mylan alleges that Teva used various tactics to delay competition and maintain its monopoly on Copaxone, costing the U.S. healthcare system billions in excess spending.
Morgantown-based Mylan Pharmaceuticals—not its parent Viatris—filed the suit in U.S. District Court for the District of New Jersey against Teva and several of its subsidiaries.
2021
堪萨斯法院在EpiPen集体诉讼中作出大体有利于迈蓝的裁决
裁决
美国堪萨斯联邦地区法院在一宗与EpiPen自动注射器有关的集体诉讼中，就迈蓝的简易判决动议作出大体有利于迈蓝的裁决。法院驳回了原告依据联邦《反敲诈勒索及受贿组织法》提出的主张，以及关于迈蓝通过返利安排排挤品牌竞争的主张。法院未就剩余主张的实体问题作出裁决。
美国堪萨斯联邦地区法院在一宗与EpiPen自动注射器有关的集体诉讼中，就Mylan的简易判决动议作出大体有利于Mylan的裁决。法院驳回了原告依据联邦《反敲诈勒索及受贿组织法》提出的主张，以及关于Mylan通过返利安排排挤品牌竞争的主张。法院未就剩余主张的实体问题作出裁决。
来源摘录
Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class action related to EpiPen® Auto-Injector.
The company is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers.
The only remaining claim in this class action pertains to a patent settlement between Pfizer and Teva and other alleged actions regarding the launch of Teva's generic epinephrine auto-injector. Today's ruling was not a decision on the merits of that claim
2020
法院在 Sanofi 诉讼中作出有利于 Mylan 的简易判决
裁决
美国堪萨斯州联邦地区法院在 Sanofi 因 EpiPen 产品提起的诉讼中作出有利于 Mylan 的简易判决。Viatris 称法院此举驳回了 Sanofi 关于反竞争行为的主张；来源报道的是判决，并未另行认定存在不当行为。
来源摘录
Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products.
it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen
2016
2013
2009
1998